What's next in psoriatic arthritis therapy? A look at the pipeline

Purpose of review Psoriatic arthritis (PsA) outcomes have improved, yet many patients do not achieve sustained control, and a meaningful proportion develop difficult-to-treat disease. This review summarizes relevant new therapies in the PsA pipeline and highlights emerging strategies likely to shape near-term care, including interception, metabolic targeting, combination/sequence approaches, and early precision-medicine efforts. Recent findings Pipeline innovation clusters in three areas: interleukin (IL)-17 pathway advances, including dual IL-17A/IL-17F blockade and engineered formats (nanobodies/small scaffolds) that may alter tissue pharmacology; selective tyrosine kinase 2 inhibition (allosteric and highly selective catalytic-site inhibitors) expanding oral options; and oral IL-23 receptor antagonism progressing from strong psoriasis efficacy into phase 3 PsA development. Beyond new molecules, strategies are evolving. Exploratory evidence supports further evaluation of dual-targeted approaches for highly refractory PsA, while metabolic targeting with incretin-based therapy is being tested as an adjunct to immunomodulation to address obesity-linked inflammatory amplification and cardiometabolic risk. EULAR transition frameworks, prodromal musculoskeletal symptoms and imaging abnormalities support a plausible interception window in at risk psoriasis. Summary The next wave in PsA will be defined by both new agents and smarter strategies: more oral/selective therapies, testing interception in risk-enriched psoriasis, integrating metabolic approaches, and evaluating optimized sequencing and selected combination therapy while precision tools mature.